TLX Investors Have Opportunity to Lead Class‑Action Against Telix Pharmaceuticals

Rosen Law Firm has filed a securities‑class action lawsuit on behalf of investors who bought securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025 (inclusive). The firm is now reminding those investors of a critical deadline: to be considered as lead plaintiff, they must file a motion by January 9, 2026. According to the complaint, Telix and certain defendants allegedly made materially false or misleading statements, or omitted key information — specifically overstating the progress of Telix’s prostate‑cancer therapeutic candidates, as well as exaggerating the quality of its supply chain and business partners. As a result, statements about the company’s operations, future prospects and business outlook are claimed to have lacked a reasonable basis. When the truth came out, investors suffered financial losses. If you purchased Telix securities during the class period, you may be eligible for compensation under a contingency‑fee arrangement (meaning no upfront costs). To join, or for questions about your rights, you can submit a form provided by Rosen Law Firm, or contact attorney Phillip Kim. Note that no class has yet been certified — until certification, you are not formally represented by counsel unless you retain one, though you may opt to join or remain an absent class member. #Telix #SecuritiesClassAction #InvestorRights #RosenLawFirm #SlimScan #GrowthStocks #CANSLIM